Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

C4 Therapeutics Inc (CCCC)

120 + Investors. Track Smart Money conviction in CCCC. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +20
Streak
2Q ▲
Buyers last Q
62%

Smart Money Signals — CCCC

Based on 121 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
121 hedge funds hold CCCC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +6% more funds vs a year ago

fund count last 6Q
+7 new funds entered over the past year (+6% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction. The peak was reached in just 4 quarters from the low — a sharp move.
🟢

More buyers than sellers — 62% buying

73 buying45 selling
Last quarter: 73 funds were net buyers (32 opened a brand new position + 41 added to an existing one). Only 45 were sellers (33 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+10 vs last Q)

new funds entering per quarter
Funds opening a new CCCC position: 25 → 24 → 22 → 32. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

45% of holders stayed for 2+ years

45% conviction (2yr+) 23% medium 32% new
54 out of 121 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +38% but shares only +3% — price-driven

Value
+38%
Shares
+3%
Last quarter: the total dollar value of institutional holdings rose +38%, but actual share count only changed +3%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📈

Growing discovery — still being found

27 → 25 → 24 → 22 → 32 new funds/Q
New funds entering each quarter: 25 → 24 → 22 → 32. A growing number of institutions are discovering CCCC each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 55% veterans vs 34% newcomers

55% veterans 11% 1-2yr 34% new
Entry-cohort mix of 127 holders: 70 (55%) are 2+ year veterans, 14 entered 1–2 years ago, and 43 (34%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.

Strong quality — 33% AUM from major funds

33% from top-100 AUM funds
28 of 121 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.9
out of 10
Low Exit Risk
Exit risk score 3.9/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CCCC

In 2026 Q1, 73 hedge funds were net buyers of CCCC (32 opened a new position, 41 added to an existing one), while 45 reduced or exited (33 trimmed, 12 sold completely) — a 62% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. 33% of total institutional value in CCCC is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +20 funds (more new holders than closures). Total institutional holders: 121.

Hedge Fund Ownership: CCCC

How many hedge funds hold CCCC — quarterly history vs. share price
Quarterly hedge fund ownership of CCCC vs. share price

Market Analysis: CCCC

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CCCC

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy C4 Therapeutics Inc (CCCC) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CCCC has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 77d ago
CCCC
+45.2%
XLV
nan%

CCCC outperformed XLV by nan% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 32d ago
CCCC
+7.3%
XLV
nan%

Since the filing became public, CCCC outperformed XLV by nan% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

7 top-rated funds 2 high-conviction
Consensus
3.9
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: CCCC
120 + Investors

Track Smart Money conviction in CCCC. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 120 101 18.81%
13F Shares 83M 80M 3.22%
Total Value $211M $153M 38.27%
New Positions 31 22 +9
Increased Positions 39 44 -5
Closed Positions 12 19 -7
Reduced Positions 31 21 +10
Total Calls 4 3 33.33%
Total Puts 2 3 -33.33%
PUT/CALL Ratio 0.5 1.0 Bullish

Statistics: CCCC

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

120 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CCCC. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CCCC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Lynx1 Capital Management LP 2.91% 6,998,902 $18.4M
2 Squadron Capital Management LLC 2.17% 2,250,000 $5.9M
3 Bain Capital Life Sciences Investors, LLC 1.70% 7,171,910 $18.9M
4 Silverarc Capital Management, LLC 0.51% 1,911,785 $5.0M
5 Soleus Capital Management, L.P. 0.41% 3,803,942 $10.0M
6 Verdad Advisers, LP 0.32% 109,407 $288K
7 Platinum Investment Management Ltd 0.26% 384,766 $1.0M
8 Stempoint Capital LP 0.23% 453,236 $1.2M
9 Ra Capital Management, L.P. 0.22% 8,000,000 $21.0M
10 Intrepid Family Office LLC 0.13% 60,000 $158K
11 Vienna Powszechne Towarzystwo Emerytalne S.A. Vienna Insurance Group 0.09% 85,000 $224K
12 CTC Alternative Strategies, Ltd. 0.06% 10,792 $28K
13 Wasatch Advisors LP 0.05% 2,961,761 $7.8M
14 Seven Fleet Capital Management LP 0.05% 57,076 $150K
15 Orbimed Advisors LLC 0.04% 856,353 $2.3M
16 683 Capital Management, LLC 0.04% 300,000 $789K
17 Axq Capital, LP 0.03% 86,278 $227K
18 Dauntless Investment Group, LLC 0.03% 15,000 $39K
19 Atom Investors LP 0.03% 136,047 $358K
20 Diametric Capital, LP 0.02% 34,594 $91K
21 Hennion & Walsh Asset Management, Inc. 0.02% 223,168 $587K
22 Northern Lights Advisors, Inc. 0.02% 12,930 $25K
23 Blackston Financial Advisory Group, LLC 0.02% 10,000 $26K
24 Congress Asset Management Co 0.02% 830,624 $2.2M
25 Catalyst Funds Management Pty Ltd 0.01% 25,740 $68K
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — C4 Therapeutics Inc (CCCC)

What does the Smart Money Trend signal show for CCCC?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added CCCC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CCCC?

More buyers than sellers — 62% buying: Last quarter: 73 funds were net buyers (32 opened a brand new position + 41 added to an existing one). Only 45 were sellers (33 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CCCC holders?

Strong quality — 33% AUM from major funds: 28 of 121 holders rank in the top 100 by AUM, accounting for 33% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CCCC?

45% of holders stayed for 2+ years: 54 out of 121 hedge funds have held CCCC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy C4 Therapeutics Inc (CCCC) following the 2026 Q1 hedge fund 13F filings?

As of today, CCCC has moved +7.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to nan% for the XLV sector ETF — an outperformance of nan%. Since the quarter end (March 31, 2026), CCCC has gained +45.2% vs nan% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →